Vinge Logotype
Svenska English 18D7E0DE-2035-40AE-A740-8F45A358A8F4 Login
  1. Home
  2. Mandates
  3. Vinge is advising Vimian Group AB (publ) (“Vimian”) and the principal shareholder Fidelio Capital AB (“Fidelio”) in connection with a private placement and subsequent listing on Nasdaq First North Growth Market with first day of trading on 18 June 2021
Mandate

Vinge is advising Vimian Group AB (publ) (“Vimian”) and the principal shareholder Fidelio Capital AB (“Fidelio”) in connection with a private placement and subsequent listing on Nasdaq First North Growth Market with first day of trading on 18 June 2021

June 18, 2021 Banking and Finance M&A

Vinge is advising Vimian and the principal shareholder Fidelio in connection with a private placement and subsequent listing on Nasdaq First North Growth Market with first day of trading on 18 June 2021, and also with the reorganization preceding the listing. The price in the private placement values Vimian to c. SEK 29.6 billion.

The Vinge team primarily consists of Jonas Bergström, Dain Hård Nevonen, Linnéa Sellström, Johanna Wiberg, Hanna Risberg, Anders Sundin Lundberg, Matthias Pannier, Stina Bengtsson, Manne Bergström, Annika Nyberg Ekenberg, Benjamin Vafaeian, Amanda Steen and Annie Fällström. Albert Wållgren, Linn Adelwald, Josefine Lanker, Seyran Sahin,  Felix Möller, Caroline Krassén and  Lave White advises on financing matters and VDR assistant Nathalie Hughes .

Related

Vinge advises Axcel VI and Currentum in connection with the acquisition of Elprojekt Skandinavien

 Vinge advises Axcel VI and the Currentum Group in connection with the acquisition of Elprojekt Skandinavien. The company provides complete electrical installations throughout Sweden, focusing on new construction of logistics properties, production facilities, residential buildings and office buildings. Elprojekt Skandinavien had a revenue of SEK 316 million in 2024.
June 23, 2025

Vinge advises Meribel Pharma Solutions

 Vinge advises Meribel Pharma Solutions in connection with the sale of a production facility specialising in the manufacture of antibiotics to Apotek Produktion & Laboratorier AB ("APL").
June 23, 2025

Vinge has advised Hansa Biopharma in connection with a directed share issue of approx. SEK 232 million and restructuring of debt financing

 Vinge has advised Hansa Biopharma AB (publ) in connection with a directed share issue, through which Hansa raises gross proceeds of approx. SEK 232 million, and restructuring of debt financing. As part of such debt restructuring, Hansa has in conjunction with the directed share issue set-off debt corresponding to approximately USD 14.9 million of its total debt amount.
June 23, 2025